Introduction to biological and small molecule drug research and development


C Robin Ganellin, Roy Jefferis and Stanley Roberts (eds)
Elsevier
2013 | 466pp | £59.99
ISBN 9780123971760
Reviewed by Graham Wynne
http://rsc.li/CW_021404
 
Drug discovery is not just about small molecules. Biopharmaceutical drugs (proteins, antibodies etc) represent an increasing proportion of newly approved medicines, and there is no sign of that trend slackening. However, while the majority of medicinal chemists dealing with small molecules would be able to name examples, and have some general awareness of biological drugs, that is likely to be the extent of their knowledge.
 
This book, which essentially forms a companion set with the related 1992 text by the same team, aims to address this situation. The editors have assembled a range of case studies drawn from leading institutes and authors in the field. These attempt to demystify the evolution and development of biopharmaceutical drugs, through comparisons with recent developments in, and perspectives from, the small molecule arena. 
 
Groundwork is provided by introductory chapters that cover the basic theories pertinent to each class of agent. Pleasingly, both mainstream therapeutic areas, including oncology and diabetes, and orphan diseases such as lysosomal storage disorders are represented. 
 
There are some excellent and very readable case studies, and the two chapters that provide a more basic introduction to this subject area are also noteworthy. Although there is some duplication here, a wealth of valuable and easy assimilated information is presented that quickly gives the reader a grasp of the different challenges facing biopharmaceutical drugs and their developers.
 
There are a few errors, and it was surprising to find a complete lack of chemical structures in the chapter comparing small molecule and biopharmaceutical treatments for diabetes. Similarly, I would question the order of the text; the case studies are interrupted by a review of the biopharmaceutical industry, which, although it contains useful information, feels like it should appear nearer the start of the book.
 
This text will be of particular interest both to the medicinal chemist who is looking to increase their knowledge beyond the small molecules area, and those with experience in the biologics field.
 
 

Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

Re-arming the antibiotic arsenal

26 September 2013 Feature

news image

How can we make new antibiotics? Phillip Broadwith takes a look

Most Commented

Lithium–sulfur batteries ready to go the distance

3 December 2013 Research

news image

Innovative electrodes set to put electric cars in the fast lane with a new design that holds double the energy of ordinary li...

Graphene made in a kitchen blender

22 April 2014 Research

news image

High quality flakes of two-dimensional material exfoliated from graphite points way to bulk production